ALPN:NSD-Alpine Immune Sciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.05

Change

+0.14 (+2.03)%

Market Cap

USD 0.31B

Volume

0.10M

Avg Analyst Target

USD 25.00 (+254.61%)

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

ALPN Stock Forecast & Price:
Based on the Alpine Immune Sciences Inc stock forecasts from 1 analysts, the average analyst target price for Alpine Immune Sciences Inc is USD 25.00 over the next 12 months. Alpine Immune Sciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Alpine Immune Sciences Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Alpine Immune Sciences Inc’s stock price was USD 7.05. Alpine Immune Sciences Inc’s stock price has changed by -4.08% over the past week, -11.88% over the past month and -35.91% over the last year.

About Alpine Immune Sciences Inc (ALPN:NSD)

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an induc ...Read More

Company Website : https://www.alpineimmunesciences.com

Address : 188 East Blaine Street, Seattle, WA, United States, 98102

Employees : 85

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.59

52 Week High : 14.40

Short Ratio : 29.23

52 Week Low : 6.00

Shorted Shares : 1,369,505

200 Day Moving Average : 8.91

Shorted Shares Previous Month : 1,397,793

50 Day Moving Average : 8.18

Shares Held By Insiders : 10.06%

Short Percentage : 8.97%

Shares Held by Institutions : 79.63%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+8.91 (+1.30%)

 USD74.83B 13.56 10.63
VRTX Vertex Pharmaceuticals Inc

+7.96 (+2.88%)

 USD72.69B 23.18 15.56
MRNA Moderna Inc

+2.54 (+2.12%)

 USD48.37B 3.83 2.59
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.65 (+2.08%)

 USD31.55B 2.99 1.31
RPRX Royalty Pharma Plc

+0.35 (+0.88%)

 USD27.26B 39.16 19.50
SGEN Seagen Inc

+0.08 (+0.06%)

 USD24.95B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

+5.22 (+2.64%)

 USD23.69B N/A -31.40
GMAB Genmab AS

+0.30 (+0.95%)

 USD21.80B 40.29 3.47
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ALPN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.10% 55% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.10% 54% F 32% F
Trailing 12 Months  
Capital Gain -37.67% 77% C+ 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.67% 77% C+ 44% F
Trailing 5 Years  
Capital Gain -39.12% 62% D- 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.12% 61% D- 27% F
Average Annual (5 Year Horizon)  
Capital Gain 35.19% 83% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.19% 83% B 86% B
Risk Return Profile  
Volatility (Standard Deviation) 116.31% 14% F 10% F
Risk Adjusted Return 30.26% 80% B- 66% D
Market Capitalization 0.31B 66% D 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.10 44% F 37% F
Price / Cash Flow Ratio -20.35 91% A- 75% C
EV/EBITDA -1.14 56% F 61% D-
Management Effectiveness  
Return on Equity -75.73% 39% F 21% F
Return on Invested Capital -49.65% 52% F 25% F
Return on Assets -17.50% 77% C+ 28% F
Debt to Equity Ratio 2.80% 77% C+ 80% B-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 29.23 3% F 1% F
Short Percent 8.97% 23% F 18% F
Beta 1.59 26% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.